List view / Grid view
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
Cannabidiol's (CBD) anti-inflammatory properties could be harnessed to treat or prevent COVID-19, according to a new study.
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
A new compound can inhibit the build-up of plaque in arteries and prevent atherosclerosis, researchers have shown.
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
